Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Bausch Health Companies Inc. (BHC) Insider Trading Activity
Healthcare • Drug Manufacturers - Specialty & Generic • 20,270 employees
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Total Value
-$1,880,272.02
Total Shares
937,180
Average Trade Value
-$104,459.56
Most Active Insider
Appio Thomas
Total Activity: $1,538,957
Largest Single Transaction
$721,018
by Appio Thomas on Feb 28, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Executive Officer
Director, Officer
|
Feb 28, 2025 | 24,838 | $184,795 | 1,965,260 (-1.3%) | Payment of Exercise Price | |
|
Evp, General Counsel
Officer
|
Feb 28, 2025 | 26,325 | $195,858 | 564,292 (-4.7%) | Payment of Exercise Price | |
|
Svp, Controller Cao
Officer
|
Feb 28, 2025 | 2,865 | $21,316 | 197,364 (-1.5%) | Payment of Exercise Price | |
|
Svp, Controller Cao
Officer
|
Feb 28, 2025 | 5,096 | $37,914 | 192,268 (-2.7%) | Payment of Exercise Price | |
|
Chief Executive Officer
Director, Officer
|
Feb 28, 2025 | 85,100 | $633,144 | 1,880,160 (-4.5%) | Payment of Exercise Price | |
|
Chief Executive Officer
Director, Officer
|
Feb 28, 2025 | 96,911 | $721,018 | 1,783,249 (-5.4%) | Payment of Exercise Price | |
|
Evp, General Counsel
Officer
|
Feb 28, 2025 | 5,994 | $44,595 | 607,590 (-1.0%) | Payment of Exercise Price | |
|
Evp, General Counsel
Officer
|
Feb 28, 2025 | 16,973 | $126,279 | 590,617 (-2.9%) | Payment of Exercise Price | |
|
Chief Executive Officer
Director, Officer
|
Feb 26, 2025 | 635,425 | $0 | 1,990,098 (+31.9%) | Grant | |
|
Evp, Us Pharma
Officer
|
Feb 26, 2025 | 108,311 | $0 | 252,663 (+42.9%) | Grant | |
|
Evp, General Counsel
Officer
|
Feb 26, 2025 | 180,518 | $0 | 613,584 (+29.4%) | Grant | |
|
Evp, CFO
Officer
|
Feb 26, 2025 | 216,622 | $0 | 515,460 (+42.0%) | Grant | |
|
Svp, Controller Cao
Officer
|
Feb 26, 2025 | 49,823 | $0 | 200,229 (+24.9%) | Grant | |
|
Director
|
Dec 31, 2024 | 852 | $6,867 | 207,946 (+0.4%) | Grant | |
|
Director
|
Dec 31, 2024 | 4,109 | $33,119 | 156,780 (+2.6%) | Grant | |
|
Director
|
Dec 31, 2024 | 7,754 | $62,497 | 268,049 (+2.9%) | Grant | |
|
Evp, General Counsel
Officer
|
Dec 2, 2024 | 440 | $3,674 | 433,066 (-0.1%) | Sale | |
|
Evp, General Counsel
Officer
|
Nov 29, 2024 | 1,692 | $14,162 | 433,506 (-0.4%) | Payment of Exercise Price |